Cargando…

Targeting the TGF-β1 Pathway to Prevent Normal Tissue Injury After Cancer Therapy

With >10,000,000 cancer survivors in the U.S. alone, the late effects of cancer treatment are a significant public health issue. Over the past 15 years, much work has been done that has led to an improvement in our understanding of the molecular mechanisms underlying the development of normal tis...

Descripción completa

Detalles Bibliográficos
Autor principal: Anscher, Mitchell S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227962/
https://www.ncbi.nlm.nih.gov/pubmed/20413640
http://dx.doi.org/10.1634/theoncologist.2009-S101
_version_ 1782217795328540672
author Anscher, Mitchell S.
author_facet Anscher, Mitchell S.
author_sort Anscher, Mitchell S.
collection PubMed
description With >10,000,000 cancer survivors in the U.S. alone, the late effects of cancer treatment are a significant public health issue. Over the past 15 years, much work has been done that has led to an improvement in our understanding of the molecular mechanisms underlying the development of normal tissue injury after cancer therapy. In many cases, these injuries are characterized at the histologic level by loss of parenchymal cells, excessive fibrosis, and tissue atrophy. Among the many cytokines involved in this process, transforming growth factor (TGF)-β1 is thought to play a pivotal role. TGF-β1 has a multitude of functions, including both promoting the formation and inhibiting the breakdown of connective tissue. It also inhibits epithelial cell proliferation. TGF-β1 is overexpressed at sites of injury after radiation and chemotherapy. Thus, TGF-β1 represents a logical target for molecular therapies designed to prevent or reduce normal tissue injury after cancer therapy. Herein, the evidence supporting the critical role of TGF-ß1 in the development of normal tissue injury after cancer therapy is reviewed and the results of recent research aimed at preventing normal tissue injury by targeting the TGF-ß1 pathway are presented.
format Online
Article
Text
id pubmed-3227962
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-32279622012-04-25 Targeting the TGF-β1 Pathway to Prevent Normal Tissue Injury After Cancer Therapy Anscher, Mitchell S. Oncologist New Translational Research in Radiation Oncology: A Tribute to Eli Glatstein With >10,000,000 cancer survivors in the U.S. alone, the late effects of cancer treatment are a significant public health issue. Over the past 15 years, much work has been done that has led to an improvement in our understanding of the molecular mechanisms underlying the development of normal tissue injury after cancer therapy. In many cases, these injuries are characterized at the histologic level by loss of parenchymal cells, excessive fibrosis, and tissue atrophy. Among the many cytokines involved in this process, transforming growth factor (TGF)-β1 is thought to play a pivotal role. TGF-β1 has a multitude of functions, including both promoting the formation and inhibiting the breakdown of connective tissue. It also inhibits epithelial cell proliferation. TGF-β1 is overexpressed at sites of injury after radiation and chemotherapy. Thus, TGF-β1 represents a logical target for molecular therapies designed to prevent or reduce normal tissue injury after cancer therapy. Herein, the evidence supporting the critical role of TGF-ß1 in the development of normal tissue injury after cancer therapy is reviewed and the results of recent research aimed at preventing normal tissue injury by targeting the TGF-ß1 pathway are presented. AlphaMed Press 2010-04 /pmc/articles/PMC3227962/ /pubmed/20413640 http://dx.doi.org/10.1634/theoncologist.2009-S101 Text en ©AlphaMed Press available online without subscription through the open access option.
spellingShingle New Translational Research in Radiation Oncology: A Tribute to Eli Glatstein
Anscher, Mitchell S.
Targeting the TGF-β1 Pathway to Prevent Normal Tissue Injury After Cancer Therapy
title Targeting the TGF-β1 Pathway to Prevent Normal Tissue Injury After Cancer Therapy
title_full Targeting the TGF-β1 Pathway to Prevent Normal Tissue Injury After Cancer Therapy
title_fullStr Targeting the TGF-β1 Pathway to Prevent Normal Tissue Injury After Cancer Therapy
title_full_unstemmed Targeting the TGF-β1 Pathway to Prevent Normal Tissue Injury After Cancer Therapy
title_short Targeting the TGF-β1 Pathway to Prevent Normal Tissue Injury After Cancer Therapy
title_sort targeting the tgf-β1 pathway to prevent normal tissue injury after cancer therapy
topic New Translational Research in Radiation Oncology: A Tribute to Eli Glatstein
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227962/
https://www.ncbi.nlm.nih.gov/pubmed/20413640
http://dx.doi.org/10.1634/theoncologist.2009-S101
work_keys_str_mv AT anschermitchells targetingthetgfb1pathwaytopreventnormaltissueinjuryaftercancertherapy